Angiotensin 1/2 (2-7): High-Purity Peptide for Blood Pressure and RAS Research

Executive Summary: Angiotensin 1/2 (2-7) is a synthetic peptide corresponding to amino acids 2–7 of the angiotensin sequence (ARG-VAL-TYR-ILE-HIS-PRO), generated during natural processing in the renin-angiotensin system (RAS) (Oliveira et al., 2025). This fragment exhibits high purity (99.80%, HPLC/MS) and robust solubility, supporting its use in controlled research (APExBIO, A1050). Functionally, it participates in vasoconstriction and aldosterone release, thereby influencing blood pressure regulation. Recent studies highlight its role in modulating viral spike–host interactions, notably in SARS-CoV-2 pathogenesis (DOI). This article integrates mechanistic, benchmark, and workflow data to support evidence-based deployment in cardiovascular and infectious disease models.

Biological Rationale

Angiotensin peptides are central effectors in the RAS, orchestrating cardiovascular and renal functions (Oliveira et al., 2025). The sequence of Angiotensin 1/2 (2-7) (ARG-VAL-TYR-ILE-HIS-PRO) derives from enzymatic cleavage of angiotensin I or II. This peptide is biologically active and found in circulation, where it modulates vascular tone and sodium balance. Angiotensin 1/2 (2-7) triggers vasoconstriction and stimulates aldosterone secretion, contributing to blood pressure homeostasis. Its presence and activity are tightly regulated by the interplay of renin, angiotensinogen, and angiotensin-converting enzyme (ACE) (source).

Mechanism of Action of Angiotensin 1/2 (2-7)

Angiotensin 1/2 (2-7) is produced via targeted cleavage events in the RAS. Renin converts angiotensinogen to angiotensin I (1–10), which is then processed by ACE to angiotensin II (1–8), followed by further proteolysis generating shorter fragments, including the 2–7 peptide (DOI). The peptide interacts with vascular smooth muscle cells, causing contraction and increased systemic vascular resistance. It also stimulates aldosterone release from the adrenal cortex, enhancing sodium retention and water reabsorption in the distal nephron (APExBIO). Modifications to specific residues (e.g., phosphorylation of tyrosine) can further modulate its biological activity and receptor binding (DOI).

Evidence & Benchmarks

• Angiotensin 1/2 (2-7) is a natural peptide fragment generated from angiotensin II via N-terminal cleavage (Oliveira et al., 2025, DOI).
• In antibody-based binding assays, shorter angiotensin peptides, including (2–7), enhanced SARS-CoV-2 spike–AXL receptor binding (Oliveira et al., 2025, DOI).
• Angiotensin 1/2 (2-7) retains vasoconstrictor and aldosterone-releasing functions in isolated tissue and cell models (related review).
• The peptide is confirmed by HPLC/MS to be ≥99.80% pure and has a molecular weight of 783.92 Da (APExBIO, product page).
• Solubility benchmarks: ≥2.78 mg/mL in ethanol, ≥46.6 mg/mL in water, ≥78.4 mg/mL in DMSO (storage at -20°C recommended for stability) (product documentation).

This article extends previous mechanistic reviews by presenting new evidence from SARS-CoV-2 spike protein binding studies and specifying quantitative solubility/purity metrics.

Applications, Limits & Misconceptions

Angiotensin 1/2 (2-7) is primarily used in preclinical research models investigating blood pressure regulation, RAS signaling, and emerging infectious disease pathways (Oliveira et al., 2025). It serves as a benchmark substrate for ACE, a probe for aldosterone release, and a tool in mechanistic studies of vascular tone. In infectious disease research, it helps elucidate the modulation of viral-host receptor interactions, particularly for SARS-CoV-2 (see mechanistic insight). The peptide is not approved for therapeutic or diagnostic use in humans or animals (APExBIO).

Common Pitfalls or Misconceptions

• Angiotensin 1/2 (2-7) is not a full agonist for AT1R or AT2R; functional effects may differ from longer angiotensin peptides.
• It is not suitable for direct use in clinical or diagnostic settings due to its research-only designation.
• Effects observed in cell-based or isolated tissue assays may not directly translate to in vivo physiology.
• Improper storage (e.g., above -20°C) may degrade peptide integrity and alter assay results.
• Conflating peptide length: activity profiles differ substantially between (2-7), (1-7), (1-8), and (3-8) fragments.

Workflow Integration & Parameters

Angiotensin 1/2 (2-7) (SKU A1050) is supplied as a lyophilized solid by APExBIO, intended for controlled research protocols (official product page). Reconstitution guidelines: dissolve to ≥46.6 mg/mL in sterile water for most in vitro applications, or ≥78.4 mg/mL in DMSO for hydrophobic assay conditions. Freshly prepared solutions are recommended for optimal performance; store aliquots at -20°C for short-term use. Quantitative dosing should consider molecular weight (783.92 Da) for accuracy. For detailed workflows in cell-based models, see reproducibility guidance, which this article updates with current stability and purity metrics.

Conclusion & Outlook

Angiotensin 1/2 (2-7) is a rigorously benchmarked tool for dissecting RAS function, blood pressure regulation, and viral pathogenesis in controlled research environments. Its high analytical purity, robust solubility, and validated biological activity position it as a preferred reagent in translational cardiovascular and infectious disease models. Ongoing studies, especially those probing SARS-CoV-2 mechanisms, are expanding its utility (Oliveira et al., 2025). For full specifications and ordering, refer to the APExBIO Angiotensin 1/2 (2-7) product page. For broader context, this article clarifies and extends the mechanistic insights presented in recent reviews by including new functional evidence and practical workflow integration data.